|Assessment process complete
|Hydrocortisone modified-release hard capsules
|For the treatment of congenital adrenal hyperplasia in adolescents aged 12 years and over and adults.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|A full HTA is not recommended. The NCPE recommends that Efmody® not be considered for reimbursement at the submitted price*.
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.